John Oyler, Chief Executive Officer at BeOne Medicines Ltd. (ONC), sold 55,604 shares at $254.10 ($14.1M) on 2025-07-09, disclosed to the SEC on 2025-07-11.
Scheduled sale ($14.1M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $252.23 | 6,703 | $1.7M | 12.0% |
| 2 | $252.23 | 6,703 | $1.7M | 12.0% |
| 3 | $253.18 | 9,292 | $2.4M | 16.7% |
| 4 | $253.18 | 9,292 | $2.4M | 16.7% |
| 5 | $254.10 | 10,254 | $2.6M | 18.5% |
| 6 | $254.10 | 10,254 |
| $2.6M |
| 18.5% |
| 7 | $254.83 | 1,553 | $396K | 2.8% |
| 8 | $254.83 | 1,553 | $396K | 2.8% |
| Total | $253.38 avg | 55,604 | $14.1M | 100% |
| Filing → |
| ONC | SELL | 2026-07-17 | $20.2M | — | Filing → |
| ONC | SELL | 2026-07-17 | $89.4M | — | Filing → |
| ONC | SELL | 2026-07-14 | $18.3M | — | Filing → |